The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (−)-deprenyl research

  • K. Magyar
  • B. Szende
  • J. Lengyel
  • K. Tekes
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 48)


(−)-deprenyl cannot be considered as a simple, selective inhibitor of MAO-B. It increases the dopaminergic tone in the central nervous system by a complex mechanism. The MAO-B inhibition could result in a potentiation of the effect and the reduction of the dose of L-dopa, including the restoration of the sensitivity to L-dopa treatment, when the response to the drug has already been diminished or lost. Pre-treatment with (−)deprenyl prevent the effect of neurotoxins like MPTP, 6-hydroxydopamine, DSP-4, AF64A by inhibiting the conversion of the pretoxin to toxin, or by inhibiting the neuronal reuptake mechanisms, or the combination of the two processes. However, other effects of the inhibitor cannot be ruled out. (−)-deprenyl, but not its (+)-enantiomer, proved to be a potent inhibitor of programmed cell death (apoptosis) of PC12 cells and that of human melanoma cells, in a concentration which does not induce MAO-B inhibition. The activity of MAO-B increases with age and the age related changes led to an overproduction of neurotoxic agents. The inhibition of the enzyme activity can play a preventive role against neurodegenerative brain disorders. The most widely used MAO-B inhibitor in the therapy is (−)-deprenyl and it lacks the “cheese reaction”. The complex mechanism for the lack of the former effect is not fully known.


PC12 Cell Monoamine Oxidase Cheese Effect Deprenyl Treatment Neurodegenerative Brain Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ansari KS, Tatton WG, Yu PH, Kruck TPA (1993) Rescue of axotomised immature rat facial motoneurons by R(−)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042–4053PubMedGoogle Scholar
  2. Barber AJ, Paterson lA, Gelowitz DL, Voll CL (1993) Deprenyl protects rat hippocampal pyramidal cells from ischaemic insult. Soc Neurosci Abstr 19: P1646Google Scholar
  3. Berry MD, Juorio AV, Paterson IA (1994) The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 42: 375–391PubMedCrossRefGoogle Scholar
  4. Bertocci B, Gill G, Da Prada M (1988) Prevention of the DSP-4-induced noradrenergic neurotoxicity by irreversible, not by reversible MAO-B inhibitors. Pharmacol Res Commun 20: 131–132CrossRefGoogle Scholar
  5. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect of L-dopa treatment by an inhibitor of MAO-B, l-deprenyl. J Neural Transm 36: 303–336PubMedCrossRefGoogle Scholar
  6. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Martin J (1985) Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–128PubMedCrossRefGoogle Scholar
  7. Brodie BB, Cho AK, Gessa GL (1970) Possible role of p-hydroxynorephedrine in the depletion of norepinephrine induced by d-amphetamine and in tolerance to this drug. In: Costa E, Garattini S (eds) Amphetamines and related compounds. Raven Press, New York, pp 217–230Google Scholar
  8. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (−)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517–521PubMedCrossRefGoogle Scholar
  9. Clow A, Hussain T, Glover V, Sandler M, Dexter DT, Walker M (1991) (−)-deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm 86: 77–80CrossRefGoogle Scholar
  10. Da Prada M (1991) New approaches to the treatment of age-related brain disorders. Can J Neurol Sci 18: 384–386PubMedGoogle Scholar
  11. Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE (1984) The pharmacology of Parkinson’s disease: basic aspects and recent advances. Experiencia 40: 1165–1172CrossRefGoogle Scholar
  12. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Marti JS (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29: 279–292Google Scholar
  13. Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G (1988) MAO-B activity and the psychopathology of Parkinson’s disease, senile dementia and multiinfarction dementia. Acta Psychiatr Scand 78: 730–736PubMedCrossRefGoogle Scholar
  14. Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man; a selective monoamine oxidase B inhibitor without the “Cheese effect”. Psychopharmacology 57: 33–38PubMedCrossRefGoogle Scholar
  15. Finnegan KT, Skratt JS, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184: 119–126PubMedCrossRefGoogle Scholar
  16. Fowler CJ, Strolin-Benedetti M (1983) The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimaxatone. J Neurochem 40: 1534–1541PubMedCrossRefGoogle Scholar
  17. Gibson CJ (1987) Inhibition of MAO-B, but not MAO-A blocks DSP-4 toxicity on central NE neurons. Eur J Pharmacol 141: 135–138PubMedCrossRefGoogle Scholar
  18. Glover V, Sandler M (1986) Clinical chemistry of monoamine oxidase. Cell Biochem Func 4: 89–97CrossRefGoogle Scholar
  19. Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80–81PubMedCrossRefGoogle Scholar
  20. Glover V, Gibb C, Sandler M (1986) The role of MAO in MPTP toxicity — a review. J Neural Transm [Suppl] 65–76Google Scholar
  21. Goldstein M, Anagnoste B (1965) The conversion in vivo of d-amphetamine to (+)-phydroxynorephedrine. Biochim Biophys Acta 107: 166–168PubMedCrossRefGoogle Scholar
  22. Hallman H, Jonsson G (1984) Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP-4 on central noradrenaline neurons. Eur J Pharmacol 103: 269–278PubMedCrossRefGoogle Scholar
  23. Harsing LG, Magyar K, Tekes K, Vizi ES, Knoll J (1979) Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acethylcholine release inhibition. Pol J Pharmacol Pharm 31: 297–307PubMedGoogle Scholar
  24. Javitch JA, d’Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173–2177PubMedCrossRefGoogle Scholar
  25. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297PubMedCrossRefGoogle Scholar
  26. Knoll J (1978) The pharmacology of selective irreversible monoamine oxidase inhibitors. In: Seiler N, Jung MJ, Koch-Weser J (eds) Enzyme activated irreversible inhibitors. Elsevier-North Holland, Amsterdam, pp 253–269Google Scholar
  27. Knoll J (1983) (−)-Deprenyl ((−)-deprenyl): the history of its development and pharmacological action. Acta Neurol Scand [Suppl] 95: 57–80CrossRefGoogle Scholar
  28. Knoll J (1985) Striatal dopamine, aging and deprenyl. In: Borsy J, Kerecsen L, Gyorgy L (eds) Proc 4th Cong Hung Pharmacol Soc Budapest 3: 7–25Google Scholar
  29. Knoll J (1987) R-(−)-Deprenyl ((−)-deprenyl, Mogervan®) facilitates the activity of the nigro-striatal dopaminergic neuron. J Neural Transm 25: 45–66Google Scholar
  30. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (−)-deprenyl. Mech Aging Dev 46: 237–262PubMedCrossRefGoogle Scholar
  31. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408PubMedGoogle Scholar
  32. Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), and new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155: 154–164PubMedGoogle Scholar
  33. Ladányi A, Timár J, Paku S, Molnár G, Lapis K (1990) Selection and characterization of human melanoma lines with different liver-colonizing capacity. Int J Cancer 46: 456–461PubMedCrossRefGoogle Scholar
  34. Lai CT, Zuo DM, Yu PH (1994) Is brain superoxide dismutase activity increased following chronic treatment with L-deprenyl? J Neural Transm 41: 221–229Google Scholar
  35. Landau WM (1990) Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology 40: 1337–1339PubMedGoogle Scholar
  36. Langston JW (1980) (−)-deprenyl as neuroprotective therapy in Parkinson’s disease: concepts and controversies. Neurology [Suppl3] 40: 61–66Google Scholar
  37. Magyar K (1991) Neuroprotective effect of deprenyl and p-fluor-deprenyl. Second Congress Paneuropean Society of Neurology, Vienna, p26Google Scholar
  38. Magyar K (1992) Pharmacology of monoamine oxidase type B inhibitors. In: Szelenyi I (ed) Inhibitors of monoamine oxidase B. Birkhäuser, Basel, pp 125–143Google Scholar
  39. Magyar K (1994) Behaviour of (−)-deprenyl and its analogues. J Neural Transm 41: 167–175Google Scholar
  40. Magyar K, Knoll J (1970) Effect of phenyl-isopropyl-methyl-propinylamine (deprenaline) on the subcellular distribution of 3H-noradrenaline. Acta Physiol Hung 37: p414Google Scholar
  41. Magyar K, Vizi ES, Ecseri Z, Knoll J (1967) Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol Hung 32: 377–387Google Scholar
  42. Murphy DL, Sunderland T, Cohen RM (1984) Monoamine oxidase-inhibiting antidepressants. Psychiat Clin North Am 7: 549–562Google Scholar
  43. Nagatsu T, Hirata Y (1987) Inhibition of the tyrosine hydroxylase system by MPTP, 1-methyl-4-phenylpiridinium ion (MPP+) and the structurally related compounds in vitro and in vivo. Eur Neurol 26 [Suppll]: 11PubMedCrossRefGoogle Scholar
  44. Naoi M, Matsuura S, Takahashi T, Nagatsu T (1989) An N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem Biophys Res Commun 161: 1213–1219PubMedCrossRefGoogle Scholar
  45. Reynolds GP, Riederer P, Rausch WD (1980) Dopamine metabolism in human brain: effects of monoamine oxidase inhibition in vitro by (−)-deprenyl and (−)tranylcypromine. J Neural Transm [Suppl] 16: 173–178Google Scholar
  46. Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E (1992) Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor l-deprenyl. Drugs Exp Clin Res VIII(5): 163–171Google Scholar
  47. Riederer P, Konradi C, Hebenstreit G, Youdim MBH (1989) Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 126: 41–45CrossRefGoogle Scholar
  48. Rinne UK (1983) A new approach to the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl95] 68:5–144Google Scholar
  49. Ross SB, Renyi AL (1976) On the long-lasting inhibitory effect of N-(2-chloroethyl)-Nethyl-2-bromobenzylamine (DSP-4) on the active uptake of adrenaline. J Pharm Pharmacol 28:458–459PubMedCrossRefGoogle Scholar
  50. Ross SB, Johansson JG, Lindborg B, Dahlbom R (1973) Cyclizing compounds. I. Tertiary N-(2-chloroethyl)-N-ethyl-2-haloalkylamine with adrenergic blocking actions. Acta Pharm Suec 10: 29–42PubMedGoogle Scholar
  51. Salach JI, Singer TP, Castagnoli N, Trevor A (1984) Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochem Biophys Res Comm 125: 831–835PubMedCrossRefGoogle Scholar
  52. Schachter M, Marsden CD, Parkes JD, Jenner P, Testa B (1980) Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiatry 43: 1016–1021PubMedCrossRefGoogle Scholar
  53. Snyder SR, Coyle JT (1969) Regional differences in 3H-norepinephrine and 3H-dopamine uptake into rat brain homogenates. J Pharmacol Exp Ther 165: 78–86PubMedGoogle Scholar
  54. Strolin-Benedetti M, Dostert P (1989) Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38: 555–561PubMedCrossRefGoogle Scholar
  55. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666–672PubMedCrossRefGoogle Scholar
  56. Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63: 1572–1575PubMedCrossRefGoogle Scholar
  57. Tekes K, Tóthfalusi L, Gaál J, Magyar K (1988) Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol Pharm 40: 653–658PubMedGoogle Scholar
  58. Tetrud JW, Langston JW (1989) The effect of deprenyl ((−)-deprenyl) on the natural history of Parkinson’s disease. Science 245: 519–522PubMedCrossRefGoogle Scholar
  59. Tipton KF (1989) In: Tipton KF, Youdim MBH (eds) Biochemical and pharmacological aspects of depression. Taylor & Francis, London, pp 1–24Google Scholar
  60. Wyllie AH, Kerr IFR, Currie AR (1986) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251–306CrossRefGoogle Scholar
  61. Youdim MBH, Finberg JPM (1986) MAO type B inhibitors as adjunct to L-dopa therapy. Adv Neurol 45: 127–136Google Scholar
  62. Yu PH, Davis BA, Fang J, Boulton AA (1994) Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4 induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63: 1820–1828PubMedCrossRefGoogle Scholar
  63. Zieher LM, Jaim-Etcheverry G (1980) Neurotoxicity of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on noradrenergic neurons is mimicked by its cyclic aziridinium derivative. Eur J Pharmacol 65: 249–256PubMedCrossRefGoogle Scholar
  64. Zsilla G, Knoll J (1982) The action of (−)-deprenyl on monoamine turnover rate in rat brain. Adv Biochem Psychopharmacol 31: 211–217PubMedGoogle Scholar
  65. Zsilla G, Barbaccia ML, Gandolfi O, Knoll J, Costa E (1983) (−)-Deprenyl, a selective MAO-B inhibitor increased 3H-imipramine binding and decreased beta-adrenergic receptor function. Eur J Pharmacol 11: 117Google Scholar

Copyright information

© Springer-Verlag/Wien 1996

Authors and Affiliations

  • K. Magyar
    • 1
  • B. Szende
    • 2
  • J. Lengyel
    • 3
  • K. Tekes
    • 1
  1. 1.Department of PharmacodynamicsSemmelweis University of MedicineBudapest VIIIHungary
  2. 2.1st Department of Pathology and Experimental Cancer ResearchHungary
  3. 3.Central Isotope LaboratorySemmelweis University of MedicineBudapestHungary

Personalised recommendations